SEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as the Company's Chief Financial Officer, effective today. Mr. Sendek brings extensive experience in senior corporate roles in biotech finance and as a highly respected senior equity research analyst at a number of leading firms.

Mr. Sendek previously served as CFO at four biotech companies: Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma. He has a successful track record in corporate finance, having completed multiple transactions, raising over $2.5B as a biotech CFO. His equity research experience includes senior roles at Stifel (Head of Healthcare Equity Research), Lazard and Oppenheimer (Head of Healthcare Life Sciences Research). The Wall Street Journal recognized Mr. Sendek as an All-Star Analyst with a #1 ranking in stock picking.